AdvisorShares Psychedelics ETF
PSIL
$24.76
-$0.49-1.93%
Rating
Reward
Risk
Fund Information
Fund Type
ETF
Category
Sub-Category
Prospectus Objective
Inception Date
Open/Closed to New Investors
Minimum Initial Investment
Minimum Subsequent Investment
Front End Fee
Back End Fee
Asset Allocation
Cash
Stock
U.S. Stock
Non U.S. Stock
Bond
U.S. Bond
Non-U.S. Bond
Preferred
Convertible
Other
Services Offered
None
Top Holdings
There are no holdings to display.
Similar ETFs
There are no ETFs to display.
Performance
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
Last Bull Market Total Return
Last Bear Market Total Return
Forward Dividend Yield
Price
1-Month Low
1-Month High
52-Week Low
52-Week High
NAV
1-Month Low
1-Month High
52-Week Low
52-Week High
Company Information
Provider
AdvisorShares
Manager/Tenure
(Years)
(Years)
Dan S. Ahrens (4)
Website
Address
AdvisorShares
2 Bethesda Metro Center, Suite 1330
Bethesda MD - 20814
2 Bethesda Metro Center, Suite 1330
Bethesda MD - 20814
Country
United States
Phone Number
877-843-3831
Investment Strategy
The investment seeks long-term capital appreciation. The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.